GlassScriptPhysician profile
Amber Piercy
NPI 1629630470
$5,188.54
in general payments reported to CMS, 2019-2025
26 companies · $1,604 in 2025
The $1,604 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $565 · 2022: $690 · 2023: $1,117 · 2024: $1,212 · 2025: $1,604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,694 · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,694.24 |
| Education | $238.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,229.44 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,141.22 | 2021-2025 | Dupixent |
| Pharming Healthcare, INC. | $428.53 | 2021-2025 | Ruconest |
| Incyte Corporation | $333.75 | 2022-2025 | Opzelura, Iclusig |
| Astrazeneca Pharmaceuticals LP | $267.45 | 2021-2025 | Airsupra, Tezspire, Fasenra |
| Csl Behring | $236.16 | 2021-2025 | Haegarda, Andembry |
| Blueprint Medicines Corporation | $219.71 | 2024-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $185.54 | 2021-2024 | Takhzyro |
| Ionis Pharmaceuticals, INC. | $182.83 | 2025 | Dawnzera |
| Novartis Pharmaceuticals Corporation | $172.90 | 2021-2025 | |
| Genzyme Corporation | $161.65 | 2021-2025 | |
| Biocryst US Sales Co., LLC | $154.11 | 2023-2025 | Orladeyo |
| Leo Pharma INC. | $98.07 | 2023-2025 | Adbry, Anzupgo |
| Electromed, INC. | $77.26 | 2021-2025 | Smartvest |
| Amgen INC. | $69.54 | 2025 | Tezspire |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.24 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
| Ars Pharmaceuticals Operations, INC. | $29.24 | 2025 | Neffy |
| Verona Pharma, INC. | $27.81 | 2025 | Ohtuvayre |
| Abbvie INC. | $20.51 | 2022 | |
| Phadia US INC. | $19.14 | 2021 | |
| Xeris Pharmaceuticals, INC. | $17.88 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.79 | 2021 | |
| Grifols USA, LLC | $15.43 | 2025 | Xembify |
| Optinose US, INC. | $15.29 | 2024 | |
| Greer Laboratories, INC. | $14.36 | 2025 | Oralair |
| Hikma Pharmaceuticals USA | $13.69 | 2025 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Piercy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.